Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723773 · ClinicalTrials.gov registry record · Phase 3
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,539
- Enrollment target
NCT02723773 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 7,539 participants.
The verdict
NCT02723773, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,539 participants
- Enrollment target
Study Summary
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of older adults.
Interventions
- BIOLOGICAL Herpes Zoster Vaccine GSK1437173A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,539 participants |
| Start Date | 2016-04-16 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02723773
The ClinicalTrials.gov registry entry for NCT02723773 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Herpes Zoster Vaccine GSK1437173A is the first listed.
NCT02723773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02723773 about?
NCT02723773 is a clinical study titled "A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults". The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of...
What is the current status of trial NCT02723773?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,539 participants. The study started on 2016-04-16. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT02723773?
The interventions under investigation include: Herpes Zoster Vaccine GSK1437173A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02723773?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.